Faculty Collaboration Database

Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease. Ann Neurol 1999 Sep;46(3):419-24

Date

09/11/1999

Pubmed ID

10482276

DOI

10.1002/1531-8249(199909)46:3<419::aid-ana21>3.0.co;2-q

Scopus ID

2-s2.0-0032850453 (requires institutional sign-in at Scopus site)   369 Citations

Abstract

As part of a safety and tolerability study, a 65-year-old man with Parkinson's disease (PD) received monthly intracerebroventricular injections of glial-derived neurotrophic factor (GDNF). His parkinsonism continued to worsen following intracerebroventricular GDNF treatment. Side effects included nausea, loss of appetite, tingling, L'hermitte's sign, intermittent hallucinations, depression, and inappropriate sexual conduct. There was no evidence of significant regeneration of nigrostriatal neurons or intraparenchymal diffusion of the intracerebroventricular GDNF to relevant brain regions. Alternative GDNF delivery systems should be explored.

Author List

Kordower JH, Palfi S, Chen EY, Ma SY, Sendera T, Cochran EJ, Cochran EJ, Mufson EJ, Penn R, Goetz CG, Comella CD

Author

Elizabeth J. Cochran MD Adjunct Professor in the Pathology department at Medical College of Wisconsin

MESH terms used to index this publication - Major topics in bold

Aged
Brain
Glial Cell Line-Derived Neurotrophic Factor
Humans
Immunoenzyme Techniques
Injections, Intraventricular
Male
Nerve Growth Factors
Nerve Tissue Proteins
Neuroprotective Agents
Parkinson Disease